The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
An operational approach to National Institute on Aging–Alzheimer's Association criteria for preclinical Alzheimer disease
Open accessAbstract
OBJECTIVE: A workgroup commissioned by the Alzheimer's Association (AA) and the National Institute on Aging (NIA) recently published research criteria for preclinical Alzheimer disease (AD). We performed a preliminary assessment of these guidelines. METHODS: We employed Pittsburgh compound B positron emission tomography (PET) imaging as our biomarker of cerebral amyloidosis, and (18) fluorodeoxyglucose PET imaging and hippocampal volume as biomarkers of neurodegeneration. A group of 42 clinically diagnosed AD subjects was used to create imaging biomarker cutpoints. A group of 450 cognitively normal (CN) subjects from a population-based sample was used to develop cognitive cutpoints and to assess population frequencies of the different preclinical AD stages using different cutpoint criteria. RESULTS: The new criteria subdivide the preclinical phase of AD into stages 1 to 3. To classify our CN subjects, 2 additional categories were needed. Stage 0 denotes subjects with normal AD biomarkers and no evidence of subtle cognitive impairment. Suspected non-AD pathophysiology (SNAP) denotes subjects with normal amyloid PET imaging, but abnormal neurodegeneration biomarker studies. At fixed cutpoints corresponding to 90% sensitivity for diagnosing AD and the 10th percentile of CN cognitive scores, 43% of our sample was classified as stage 0, 16% stage 1, 12 % stage 2, 3% stage 3, and 23% SNAP. INTERPRETATION: This cross-sectional evaluation of the NIA-AA criteria for preclinical AD indicates that the 1-3 staging criteria coupled with stage 0 and SNAP categories classify 97% of CN subjects from a population-based sample, leaving only 3% unclassified. Future longitudinal validation of the criteria will be important.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Initial studies in this emerging area have identified subgroups of older adults with subtle cognitive decline that do not conform to expected patterns and investigators have designated them as Suspected Non-Alzheimer Pathology (SNAP) and Unclassified groups [51, 52].”
From Neuropsychological Criteria for Mild Cognitive Impairment Improves Diagnostic Precision, Biomarker Associations, and Progression Rates (2014) · cites this paper as [51]
Experimental — accuracy not yet measuredIn the citing paper
“Our hypothesis, therefore, can accommodate a growing realization that for many subjects with suspected AD, or who have an increased risk of developing AD, what are currently considered downstream biomarker changes potentially precede upstream biomarker changes [206-213].”
From The Alzheimer’s disease mitochondrial cascade hypothesis: progress and perspectives (2014) · cites this paper as [212]
In the citing paper
“Yet, this finding is in line with recent studies showing that AD-type atrophy and/or hypometabolism can be found in both Aβ-negative healthy controls (Jack et al., 2012) and Aβ-negative MCI patients (Prestia et al., 2013).”
From Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease and semantic dementia (2013) · cites this paper as Jack et al., 2012
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fischl, B., Salat, D. H., Busa, E., Albert, M., Dieterich, M., Haselgrove, C., van der Kouwe, A., Killiany, R., Kennedy, D., Klaveness, S., et al. (2002) · Neuron · doi:10.1016/s0896-6273(02)00569-x · Cited by 8,610
Sperling, R. A., Aisen, P. S., Beckett, L. A., Bennett, D. A., Craft, S., Fagan, A. M., Iwatsubo, T., Jack, C. R., Kaye, J., Montine, T. J., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.003 · Cited by 7,155
Self-citationHypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
Jack, C. R., Knopman, D. S., Jagust, W. J., Shaw, L. M., Aisen, P. S., Weiner, M. W., Petersen, R. C., & Trojanowski, J. Q. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70299-6 · Cited by 4,806
Self-citationImaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Self-citationMixed brain pathologies account for most dementia cases in community-dwelling older persons
Schneider, J. A., Arvanitakis, Z., Bang, W., & Bennett, D. A. (2007) · Neurology · doi:10.1212/01.wnl.0000271090.28148.24 · Cited by 1,992
Tunis (2003) · doi:10.1001/jama.290.12.1624 · Cited by 1,724
Reiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Neuropathology of older persons without cognitive impairment from two community-based studies
Bennett, D. A., Schneider, J. A., Arvanitakis, Z., Kelly, J. F., Aggarwal, N. T., Shah, R. C., & Wilson, R. S. (2006) · Neurology · doi:10.1212/01.wnl.0000219668.47116.e6 · Cited by 1,336
Dickerson, B. C., Bakkour, A., Salat, D. H., Feczko, E., Pacheco, J., Greve, D. N., Grodstein, F., Wright, C. I., Blacker, D., Rosas, H. D., et al. (2009) · Cerebral Cortex · doi:10.1093/cercor/bhn113 · Cited by 1,153
Flagged first, then by citations
Cited by
Sorted by citations
Items 101–200 of 601
The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects
Smith, R. A., Strandberg, O. T., Mattsson, N., Leuzy, A., Palmqvist, S., Pontecorvo, M. J., Devous, M. D., Ossenkoppele, R., & Hansson, O. (2020) · Brain · doi:10.1093/brain/awaa327 · Cited by 141
Nation, D. A., Edmonds, E. C., Bangen, K. J., Delano‐Wood, L., Scanlon, B. K., Han, S. D., Edland, S. D., Salmon, D. P., Galasko, D. R., & Bondi, M. W. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2014.4477 · Cited by 133
Martins, R. N., Villemagne, V., Sohrabi, H. R., Chatterjee, P., Shah, T. M., Verdile, G., Fraser, P., Taddei, K., Gupta, V. B., Rainey-Smith, S. R., et al. (2018) · Journal of Alzheimer’s Disease · doi:10.3233/jad-171145 · Cited by 129
Jack, C. R., Therneau, T. M., Wiste, H. J., Weigand, S. D., Knopman, D. S., Lowe, V. J., Mielke, M. M., Vemuri, P., Roberts, R. O., Machulda, M. M., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00323-3 · Cited by 129
Self-citationWirth, M., Haase, C. M., Villeneuve, S., Vogel, J. W., & Jagust, W. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.02.015 · Cited by 138
Rates of β-amyloid accumulation are independent of hippocampal neurodegeneration
Jack, C. R., Wiste, H. J., Knopman, D. S., Vemuri, P., Mielke, M. M., Weigand, S. D., Senjem, M. L., Gunter, J. L., Lowe, V. J., Gregg, B. E., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000386 · Cited by 129
Self-citationCan we prevent Alzheimer's disease? Secondary “prevention” trials in Alzheimer's disease
Carrillo, M. C., Brashear, H. R., Logovinsky, V., Ryan, J. M., Feldman, H., Siemers, E., Abushakra, S. R., Hartley, D. M., Petersen, R. C., Khachaturian, A. S., et al. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.12.004 · Cited by 128
Self-citationKnopman, D. S., Jack, C. R., Wiste, H. J., Lundt, E. S., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., et al. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.03.006 · Cited by 128
Self-citationPrevalence of preclinical Alzheimer disease
Kern, S., Zetterberg, H., Kern, J., Zettergren, A., Wærn, M., Höglund, K., Andréasson, U., Wetterberg, H., Börjesson‐Hanson, A., Blennow, K., et al. (2018) · Neurology · doi:10.1212/wnl.0000000000005476 · Cited by 123
Harmonized diagnostic criteria for Alzheimer's disease: recommendations
Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 122
Measuring cognition and function in the preclinical stage of Alzheimer's disease
Weıntraub, S., Carrillo, M. C., Farias, S. T., Goldberg, T. E., Hendrix, J. A., Jaeger, J., Knopman, D. S., Langbaum, J. B. S., Park, D. C., Ropacki, M. T., et al. (2018) · Alzheimer s & Dementia Translational Research & Clinical Interventions · doi:10.1016/j.trci.2018.01.003 · Cited by 129
Self-citationTargeting Cognitive Frailty: Clinical and Neurobiological Roadmap for a Single Complex Phenotype
Panza, F., Seripa, D., Solfrizzi, V., Tortelli, R., Greco, A., Pilotto, A., & Logroscino, G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150358 · Cited by 120
Biological heterogeneity in ADNI amnestic mild cognitive impairment
Nettiksimmons, J., DeCarli, C. S., Landau, S. M., Beckett, L. A., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.09.003 · Cited by 124
Hypothetical Preclinical Alzheimer Disease Groups and Longitudinal Cognitive Change
Soldan, A., Pettigrew, C. A., Cai, Q., Wang, M., Moghekar, A., O’Brien, R., Selnes, O. A., & Albert, M. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.0194 · Cited by 120
Baldeiras, I., Santana, I. J., Leitão, M. J., Gens, H., Pascoal, R., Tábuas‐Pereira, M., Beato-Coelho, J., Duro, D., Almeida, M. R., & Oliveira, C. R. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0362-2 · Cited by 123
Mormino, E. C., & Papp, K. V. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-179928 · Cited by 124
Yau, W. W., Tudorascu, D., McDade, E., Ikonomović, S., James, J. A., Minhas, D. S., Mowrey, W. B., Sheu, L. K., Snitz, B. E., Weissfeld, L. A., et al. (2015) · The Lancet Neurology · doi:10.1016/s1474-4422(15)00135-0 · Cited by 117
Bell, W. R., An, Y., Kageyama, Y., English, C., Rudow, G. L., Pletnikova, O., Thambisetty, M., O'Brien, R., Moghekar, A. R., Albert, M. S., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2018.07.215 · Cited by 111
FDG-PET in tau-negative amnestic dementia resembles that of autopsy-proven hippocampal sclerosis
Botha, H., Mantyh, W. G., Murray, M. E., Knopman, D. S., Przybelski, S. A., Wiste, H. J., Graff‐Radford, J., Josephs, K. A., Schwarz, C. G., Kremers, W. K., et al. (2018) · Brain · doi:10.1093/brain/awy049 · Cited by 112
Self-citationAβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Diagnosis and management of Alzheimer's disease: Past, present and future ethical issues
Gauthier, S. G., Leuzy, A., Racine, É., & Rosa‐Neto, P. (2013) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2013.01.003 · Cited by 119
MRI and MRS predictors of mild cognitive impairment in a population-based sample
Kantarci, K., Weigand, S. D., Przybelski, S. A., Preboske, G. M., Pankratz, V. S., Vemuri, P., Senjem, M. L., Murphy, M. C., Gunter, J. L., Machulda, M. M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31829a3329 · Cited by 112
Self-citationIs amyloid-β harmful to the brain? Insights from human imaging studies
Jagust, W. (2016) · Brain · doi:10.1093/brain/awv326 · Cited by 110
Temporal T807 binding correlates with CSF tau and phospho-tau in normal elderly
Chhatwal, J. P., Schultz, A. P., Marshall, G. A., Boot, B., Gomez-Isla, T., Dumurgier, J., LaPoint, M., Scherzer, C., Roe, A. D., Hyman, B. T., et al. (2016) · Neurology · doi:10.1212/wnl.0000000000003050 · Cited by 106
Harrington, M. G., Chiang, J., Pogoda, J. M., Gomez, M. E., Thomas, K., Marion, S., Miller, K. J., Siddarth, P., Yi, X., Zhou, F., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0079378 · Cited by 118
Suárez‐Calvet, M., Capell, A., Araque Caballero, M. Á., Morenas‐Rodríguez, E., Fellerer, K., Franzmeier, N., Kleinberger, G., Eren, E., Deming, Y., Piccio, L., et al. (2018) · EMBO Molecular Medicine · doi:10.15252/emmm.201809712 · Cited by 109
Detectable Neuropsychological Differences in Early Preclinical Alzheimer’s Disease: A Meta-Analysis
Han, S. D., Nguyen, C. P., Stricker, N. H., & Nation, D. A. (2017) · Neuropsychology Review · doi:10.1007/s11065-017-9345-5 · Cited by 121
Preferential degradation of cognitive networks differentiates Alzheimer’s disease from ageing
Chhatwal, J. P., Schultz, A. P., Johnson, K. A., Hedden, T., Jaimes, S., Benzinger, T. L. S., Jack, C., Ances, B. M., Ringman, J. M., Marcus, D. S., et al. (2018) · Brain · doi:10.1093/brain/awy053 · Cited by 101
Self-citationImaging and cerebrospinal fluid biomarkers in early preclinical alzheimer disease
Vlassenko, A. G., McCue, L., Jasielec, M. S., Su, Y., Gordon, B. A., Xiong, C., Holtzman, D. M., Benzinger, T. L. S., Morris, J. C., & Fagan, A. M. (2016) · Annals of Neurology · doi:10.1002/ana.24719 · Cited by 106
Gordon, B. A., Blazey, T., Su, Y., Fagan, A. M., Holtzman, D. M., Morris, J. C., & Benzinger, T. L. S. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2642 · Cited by 105
Guo, T., Korman, D., Baker, S. L., Landau, S. M., & Jagust, W. J. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2020.06.029 · Cited by 103
ATN profiles among cognitively normal individuals and longitudinal cognitive outcomes
Soldan, A., Pettigrew, C. A., Fagan, A. M., Schindler, S. E., Moghekar, A., Fowler, C. J., Li, Q.-X., Collins, S. J., Carlsson, C. M., Asthana, S., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000007248 · Cited by 107
Plasma Aβ but Not Tau is Related to Brain PiB Retention in Early Alzheimer’s Disease
Tzen, K., Yang, S., Chen, T., Cheng, T.-W., Horng, H. E., Wen, H.-P., Huang, Y.-Y., Shiue, C., & Chiu, M. (2014) · ACS Chemical Neuroscience · doi:10.1021/cn500101j · Cited by 105
Vos, S. J. B., Gordon, B. A., Su, Y., Visser, P. J., Holtzman, D. M., Morris, J. C., Fagan, A. M., & Benzinger, T. L. S. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.025 · Cited by 98
17q21.31 duplication causes prominent tau-related dementia with increased MAPT expression
Guennec, K. L., Quenez, O., Nicolas, G., Wallon, D., Rousseau, S., Richard, A.-C., Alexander, J., Paschou, P., Charbonnier, C., Bellenguez, C., et al. (2016) · Molecular Psychiatry · doi:10.1038/mp.2016.226 · Cited by 102
Advances in Alzheimer’s Disease Drug Development
Rafii, M. S., & Aisen, P. S. S. (2015) · BMC Medicine · doi:10.1186/s12916-015-0297-4 · Cited by 98
Effects of amyloid pathology and neurodegeneration on cognitive change in cognitively normal adults
Bilgel, M., An, Y., Helphrey, J. H., Elkins, W., Gómez, G., Wong, D. F., Davatzikos, C. A., Ferrucci, L., & Resnick, S. M. (2018) · Brain · doi:10.1093/brain/awy150 · Cited by 95
Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward
Hsu, D. C., & Marshall, G. A. (2016) · Current Alzheimer Research · doi:10.2174/1567205013666160930112125 · Cited by 95
Thomas, K. R., Edmonds, E. C., Eppig, J. S., Salmon, D. P., Bondi, M. W., & Initiative, A. D. N. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180229 · Cited by 96
Neuroimaging correlates with neuropathologic schemes in neurodegenerative disease
Lowe, V. J., Lundt, E. S., Albertson, S. M., Przybelski, S. A., Senjem, M. L., Parisi, J. E., Kantarci, K., Boeve, B., Jones, D. T., Knopman, D., et al. (2019) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2019.03.016 · Cited by 90
Self-citationPegueroles, J., Initiative, A. D. N., Jiménez, A., Vilaplana, E., Montal, V., Carmona‐Iragui, M., Pané, A., Alcolea, D. A., Videla, L., Casajoana, A., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26162 · Cited by 98
Neuronal injury biomarkers and prognosis in ADNI subjects with normal cognition
Toledo, J. B., Weiner, M. W., Wolk, D. A., Da, X., Chen, K., Arnold, S. E., Jagust, W., Jack, C., Reiman, E. M., Davatzikos, C., et al. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-26 · Cited by 89
Self-citationKantarci, K., Schwarz, C. G., Reid, R. I., Przybelski, S. A., Lesnick, T. G., Zuk, S. M., Senjem, M. L., Gunter, J. L., Lowe, V., Machulda, M. M., et al. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.1482 · Cited by 88
Self-citationJack, C. R. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1362-3 · Cited by 93
Self-citationVascular risk and Aβ interact to reduce cortical thickness in AD vulnerable brain regions
Villeneuve, S., Reed, B., Madison, C. M., Wirth, M., Marchant, N. L., Kriger, S., Mack, W. J., Sanossian, N., DeCarli, C. S., Chui, H. C., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000550 · Cited by 93
The association between tau PET and retrospective cortical thinning in clinically normal elderly
LaPoint, M. R., Chhatwal, J. P., Sepulcre, J., Johnson, K. A., Sperling, R. A., & Schultz, A. P. (2017) · NeuroImage · doi:10.1016/j.neuroimage.2017.05.049 · Cited by 84
Wolk, D. A., Sadowsky, C., Safirstein, B., Rinne, J. O., Duara, R., Perry, R. J., Agronin, M., Gamez, J., Shi, J., Ivanoiu, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.0894 · Cited by 89
Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer’s disease
González‐Ortiz, F., Kirsebom, B., Contador, J., Tanley, J. E., Selnes, P., Gísladóttir, B., Pålhaugen, L., Hemminghyth, M. S., Jarholm, J. A., Skogseth, R. E., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47286-5 · Cited by 93
Dynamic changes of CSF sTREM2 in preclinical Alzheimer’s disease: the CABLE study
Ma, L., Tan, L., Bi, Y., Shen, X., Xu, W., Ma, Y., Li, H., Dong, Q., & Yu, J. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-00374-8 · Cited by 89
Prestia, A., Caroli, A., Wade, S., van der Flier, W. M., Ossenkoppele, R., van Berckel, B. N. M., Barkhof, F., Teunissen, C. E., Wall, A. E., Carter, S. F., et al. (2015) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.12.001 · Cited by 83
A Systematic Review of Longitudinal Studies Which Measure Alzheimer’s Disease Biomarkers
Lawrence, E., Vegvari, C., Ower, A. K., Hadjichrysanthou, C., de Wolf, F., & Anderson, R. M. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-170261 · Cited by 89
Beneficial effect of bilingualism on Alzheimer's disease CSF biomarkers and cognition
Estanga, A., Ecay‐Torres, M., Ibañez, A., Izagirre, A., Villanúa, J., García‐Sebastián, M., Gaspar, M. T. I., Otaegui-Arrazola, A., Iriondo, A., Clerigue, M., et al. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.10.013 · Cited by 88
Caselli, R. J., Beach, T. G., Knopman, D. S., & Graff-Radford, N. R. (2017) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2017.02.011 · Cited by 81
Self-citationSystematic review and meta-analysis of the effects of menopause hormone therapy on cognition
Andy, C., Nerattini, M., Jett, S., Carlton, C., Zarate, C., Boneu, C., Fauci, F., Ajila, T., Battista, M., Pahlajani, S. S., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1350318 · Cited by 84
Papp, K. V., Amariglio, R. E., Mormino, E. C., Hedden, T., Dekhytar, M., Johnson, K. A., Sperling, R. A., & Rentz, D. M. (2015) · Neuropsychologia · doi:10.1016/j.neuropsychologia.2015.04.034 · Cited by 87
Suspected non-AD pathology in mild cognitive impairment
Wisse, L. E. M., Butala, N., Das, S. R., Davatzikos, C., Dickerson, B. C., Vaishnavi, S. N., Yushkevich, P. A., & Wolk, D. A. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.08.029 · Cited by 78
Association of hypometabolism and amyloid levels in aging, normal subjects
Lowe, V. J., Weigand, S. D., Senjem, M. L., Vemuri, P., Jordan, L. G., Kantarci, K., Boeve, B. F., Jack, C. R., Knopman, D. S., & Petersen, R. C. (2014) · Neurology · doi:10.1212/wnl.0000000000000467 · Cited by 83
Self-citationFunctional connectivity with the retrosplenial cortex predicts cognitive aging in rats
Ash, J. A., Lu, H., Taxier, L. R., Long, J. M., Yang, Y., Stein, E. A., & Rapp, P. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525309113 · Cited by 82
Nathan, P. J., Lim, Y. Y., Abbott, R., Galluzzi, S., Marizzoni, M., Babiloni, C., Albani, D., Bartrés‐Faz, D., Didic, M., Farotti, L., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.01.013 · Cited by 82
Serum Adiponectin Levels, Neuroimaging, and Cognition in the Mayo Clinic Study of Aging
Wennberg, A. M. V., Gustafson, D., Hagen, C. E., Roberts, R. O., Knopman, D. S., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151201 · Cited by 76
Self-citationAmyloid‐β PET in Alzheimer's disease: A systematic review and Bayesian meta‐analysis
Ruan, D., & Sun, L. (2022) · Brain and Behavior · doi:10.1002/brb3.2850 · Cited by 85
Exosomal biomarkers in Down syndrome and Alzheimer's disease
Hamlett, E. D., Ledreux, A., Potter, H., Chial, H. J., Patterson, D., Espinosa, J. M., Bettcher, B. M., & Granholm, A. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2017.08.028 · Cited by 80
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Panza, F., Solfrizzi, V., Imbimbo, B. P., & Logroscino, G. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.935332 · Cited by 80
Stögmann, E., Moser, D., Klug, S., Gleiß, A., Auff, E., Dal‐Bianco, P., Pußwald, G., & Lehrner, J. P. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150785 · Cited by 75
Wang, J., Fan, D., Li, H.-Y., He, C.-Y., Shen, Y., Zeng, G., Chen, D., Yi, X., Ma, Y., Yu, J., et al. (2022) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00512-w · Cited by 78
Neuritic and Diffuse Plaque Associations with Memory in Non-Cognitively Impaired Elderly
Malek-Ahmadi, M., Perez, S. E., Chen, K., & Mufson, E. J. (2016) · Journal of Alzheimer’s Disease · doi:10.3233/jad-160365 · Cited by 73
Plasma Tau Association with Brain Atrophy in Mild Cognitive Impairment and Alzheimer’s Disease
Deters, K., Risacher, S. L., Kim, S., Nho, K. T., West, J. D., Blennow, K., Zetterberg, H., Shaw, L. M. J., Trojanowski, J. Q., Weiner, M. W., et al. (2017) · Journal of Alzheimer s Disease · doi:10.3233/jad-161114 · Cited by 72
The neuropsychology of normal aging and preclinical Alzheimer's disease
Caselli, R. J., Locke, D. E. C., Dueck, A. C., Knopman, D. S., Woodruff, B. K., Hoffman‐Snyder, C., Rademakers, R., Fleisher, A., & Reiman, E. M. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2013.01.004 · Cited by 73
Self-citationFractional Anisotropy of the Fornix and Hippocampal Atrophy in Alzheimer’s Disease
Kantarci, K. (2014) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2014.00316 · Cited by 71
Self-citationUnrecognized preclinical Alzheimer disease confounds rs-fcMRI studies of normal aging
Brier, M. R., Thomas, J., Snyder, A. Z., Wang, L. Y., Fagan, A. M., Benzinger, T. L. S., Morris, J. C., & Ances, B. M. (2014) · Neurology · doi:10.1212/wnl.0000000000000939 · Cited by 71
Tanaka, T., Talegawkar, S. A., Jin, Y., Colpo, M., Ferrucci, L., & Bandinelli, S. (2018) · Nutrients · doi:10.3390/nu10122007 · Cited by 73
Zavecz, Z., Shah, V. D., Murillo, O. G., Vallat, R., Mander, B. A., Winer, J. R., Jagust, W. J., & Walker, M. P. (2023) · BMC Medicine · doi:10.1186/s12916-023-02811-z · Cited by 67
Knopman, D. S., Jack, C. R., Wiste, H. J., Weigand, S. D., Vemuri, P., Lowe, V. J., Kantarci, K., Gunter, J. L., Senjem, M. L., Mielke, M. M., et al. (2013) · JAMA Neurology · doi:10.1001/jamaneurol.2013.182 · Cited by 68
Self-citationVerfaillie, S. C. J., Tijms, B. M., Versteeg, A., Benedictus, M. R., Bouwman, F. H., Scheltens, P., Barkhof, F., Vrenken, H., & van der Flier, W. M. (2016) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2016.10.007 · Cited by 70
Tau imaging in the study of ageing, Alzheimer's disease, and other neurodegenerative conditions
Villemagne, V. L., & Okamura, N. (2015) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2015.09.002 · Cited by 70
Wirth, M., Oh, H., Mormino, E. C., Markley, C., Landau, S. M., & Jagust, W. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.10.012 · Cited by 70
Imaging Biomarkers Associated With Cognitive Decline: A Review
McConathy, J., & Sheline, Y. I. (2014) · Biological Psychiatry · doi:10.1016/j.biopsych.2014.08.024 · Cited by 68
Mormino, E. C., Papp, K. V., Rentz, D. M., Schultz, A. P., LaPoint, M. R., Amariglio, R. E., Hanseeuw, B. J., Marshall, G. A., Hedden, T., Johnson, K. A., et al. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.2237 · Cited by 63
Distinct pattern of hypometabolism and atrophy in preclinical and predementia Alzheimer's disease
Kljajević, V., Grothe, M. J., Ewers, M., & Teipel, S. J. (2014) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2014.04.006 · Cited by 67
Neurofilament relates to white matter microstructure in older adults
Moore, E. E., Hohman, T. J., Badami, F. S., Pechman, K. R., Osborn, K. E., Acosta, L. M. Y., Bell, S. P., Babicz, M. A., Gifford, K. A., Anderson, A. W., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.06.023 · Cited by 65
Liebsch, F., Kulic, L., Teunissen, C., Shobo, A., Ulku, I., Engelschalt, V., Hancock, M. A., van der Flier, W. M., Kunach, P., Rosa-Neto, P., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10152-w · Cited by 68
Bertens, D., Knol, D. L., Scheltens, P., Visser, P. J., & Initiative, A. D. N. (2014) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2014.05.1754 · Cited by 70
Widespread distribution of tauopathy in preclinical Alzheimer's disease
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., Morris, J. C., Ances, B. M., & Benzinger, T. L. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.022 · Cited by 65
Lee, J., Weerasinghe-Mudiyanselage, P. D. E., Kim, B., Kang, S., Kim, J., & Moon, C. (2023) · Ecotoxicology and Environmental Safety · doi:10.1016/j.ecoenv.2023.115565 · Cited by 65
Limited agreement between biomarkers of neuronal injury at different stages of Alzheimer's disease
Alexopoulos, P., Kriett, L., Haller, B., Klupp, E., Gray, K., Grimmer, T., Laskaris, N., Förster, S., Perneczky, R., Kurz, A., et al. (2014) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.03.006 · Cited by 62
Neuroimaging biomarkers and impaired olfaction in cognitively normal individuals
Vassilaki, M. E., Christianson, T. J. H., Mielke, M. M., Geda, Y. E., Kremers, W. K., Machulda, M. M., Knopman, D. S., Petersen, R. C., Lowe, V. J., Jack, C. R., et al. (2017) · Annals of Neurology · doi:10.1002/ana.24960 · Cited by 64
Self-citationTopographic staging of tau positron emission tomography images
Schwarz, A. J., Shcherbinin, S., Slieker, L. J., Risacher, S. L., Charil, A., Irizarry, M. C., Fleisher, A., Southekal, S. S., Joshi, A. D., Devous, M. D., et al. (2018) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2018.01.006 · Cited by 63
Lee, J. H., Byun, M. S., Yi, D., Choe, Y. M., Choi, H. J., Baek, H., Sohn, B. K., Lee, J., Kim, H. J., Kim, J. W., et al. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.005 · Cited by 63
Valech, N., Mollica, M. A., Olives, J., Tort‐Merino, A., Fortea, J., Lleó, A., Sánchez‐Saudinós, M. B., Molinuevo, J. L., & Rami, L. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150117 · Cited by 63
Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging
Wennberg, A. M. V., Savica, R., Hagen, C. E., Roberts, R. O., Knopman, D. S., Hollman, J. H., Vemuri, P., Jack, C. R., Petersen, R. C., & Mielke, M. M. (2016) · Journal of the American Geriatrics Society · doi:10.1111/jgs.14670 · Cited by 60
Self-citationReceptors for pro‐resolving mediators are increased in Alzheimer's disease brain
Emre, C., Hjorth, E., Bharani, K., Carroll, S., Granholm, A., & Schultzberg, M. (2020) · Brain Pathology · doi:10.1111/bpa.12812 · Cited by 60
Hu, H., Meng, L., Bi, Y., Zhang, W., Xu, W., Shen, X., Ou, Y., Ma, Y., Dong, Q., Tan, L., et al. (2021) · Alzheimer s & Dementia · doi:10.1002/alz.12377 · Cited by 58
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 61
Machulda, M. M., Hagen, C. E., Wiste, H. J., Mielke, M. M., Knopman, D. S., Roberts, R. O., Vemuri, P., Lowe, V. J., Jack, C. R., & Petersen, R. C. (2016) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1241303 · Cited by 63
Self-citationHead trauma and in vivo measures of amyloid and neurodegeneration in a population-based study
Mielke, M. M., Savica, R., Wiste, H. J., Weigand, S. D., Vemuri, P., Knopman, D. S., Lowe, V. J., Roberts, R. O., Machulda, M. M., Geda, Y. E., et al. (2013) · Neurology · doi:10.1212/01.wnl.0000438229.56094.54 · Cited by 59
Self-citationComparison of symptomatic and asymptomatic persons with primary age-related tauopathy
Besser, L. M., Crary, J. F., Mock, C., & Kukull, W. A. (2017) · Neurology · doi:10.1212/wnl.0000000000004521 · Cited by 59
Hippocampal volumes predict risk of dementia with Lewy bodies in mild cognitive impairment
Kantarci, K., Lesnick, T. G., Ferman, T. J., Przybelski, S. A., Boeve, B. F., Smith, G. E., Kremers, W. K., Knopman, D. S., Jack, C. R., & Petersen, R. C. (2016) · Neurology · doi:10.1212/wnl.0000000000003371 · Cited by 59
Self-citationAmyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old
López, O. L., Klunk, W. E., Mathis, C. A., Coleman, R., Price, J. C., Becker, J. T., Aizenstein, H. J., Snitz, B. E., Cohen, A. D., Ikonomović, M. D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000977 · Cited by 57
Certified normal: Alzheimer's disease biomarkers and normative estimates of cognitive functioning
Hassenstab, J. J., Chasse, R., Grabow, P., Benzinger, T. L. S., Fagan, A. M., Xiong, C., Jasielec, M. S., Grant, E., & Morris, J. C. (2016) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2016.03.014 · Cited by 58
Metadata
- Authors
- Jack, C. R., Knopman, D. S., Weigand, S. D., Wiste, H. J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J. L., Senjem, M. L., Ivnik, R. J., Roberts, R. O., Rocca, W. A., Boeve, B. F., & Petersen, R. C.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Jack, Clifford R.
- ORCID
- Venue
- Annals of Neurology
- Publisher
- Wiley
- Published
- 2012-04-09
- Volume
- 71
- Issue
- 6
- Pages
- 765-775
- ISSN
- 0364-5134 (ISSN-L)
- 1531-8249
- PMC
- PMC3586223
- OpenAlex
- W2044429455
- Cited by
- 602
- References
- 71
- Citations by year
- 2026: 14 · 2025: 23 · 2024: 21 · 2023: 28 · 2022: 29 · 2021: 40 · 2020: 33 · 2019: 40 · 2018: 44 · 2017: 60 · 2016: 80 · 2015: 65 · 2014: 63 · 2013: 51 · 2012: 10
- FWCI
- 27.52
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Annals of Neurology (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- Mayo Clinic
- Mayo Foundation for Medical Education and Research
- National Institute on Aging (R01AG11378, P50‐AG16574, U01AG006786, R01AG011378, R01AG041851, P50AG016574)
- National Center for Research Resources (C06RR018898)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
- Keywords
- preclinical Alzheimer's disease, NIA-AA criteria, Pittsburgh compound B PET, cerebral amyloidosis, FDG-PET, hippocampal volume, neurodegeneration biomarkers, cognitively normal older adults, diagnostic classification
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Brain, Cognition Disorders, Female, Humans, Longitudinal Studies, Male, Mental Status Schedule, Neuropsychological Tests, Thiazoles, United States, Biomarkers, Disease Progression, Fluorodeoxyglucose F18, Positron-Emission Tomography, National Institute on Aging (U.S.)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
